Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-28
2005-06-28
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C536S055200, C424S185100, C424S278100, C435S069700
Reexamination Certificate
active
06911429
ABSTRACT:
The present invention provides compositions and methods for treating a tissue disorder associated with a response-to-injury process or proliferating cells in a mammal. These tissue disorders are associated with a novel cellular phenotype designated as “transition cells” which are described herein. This cellular phenotype is characterized in having an activated erk kinase signaling activity, a stimulated AP-1 binding activity, and at least one characteristic selected from the group consisting of: (a) increased podosome formation, (b) increased flux of intracellular or extracellular hyaluronans or hyaladherins, (c) increased expression of a hyaladherin, (d) an inability to form focal adhesions, (e) increased metalloproteinase activity, and (f) increased expression of a hyaladherin. Example tissue disorders include fibrosis, inflammation, degeneration and invasive disorders such as occur in cancerous cells. The methods provided herein include administering to the mammal, an effective amount of a composition that alters the activity of transition molecules within a cell Transition molecules are shown to be comprised of hyaladherins, hyaluronans and associated molecules that regulate the transitional phenotype. A novel cell culture comprising transition cells is also provided, as well as compositions comprising particular peptides, polypeptides, and antibodies that affect the transitional phenotype.
REFERENCES:
patent: 4018884 (1977-04-01), Cleeland, Jr. et al.
patent: 4359535 (1982-11-01), Pieczenik
patent: 4376110 (1983-03-01), David et al.
patent: 4411993 (1983-10-01), Gillis
patent: 4486530 (1984-12-01), David et al.
patent: 4528266 (1985-07-01), Pieczenik
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: RE32011 (1985-10-01), Zimmerman et al.
patent: 4551433 (1985-11-01), DeBoer
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4739866 (1988-04-01), Reik et al.
patent: 4744981 (1988-05-01), Pavanasasivam
patent: 4745051 (1988-05-01), Smith
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 4816567 (1989-03-01), Snyder et al.
patent: 4851341 (1989-07-01), Hopp et al.
patent: 4870009 (1989-09-01), Evans et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4897255 (1990-01-01), Fritzberg et al.
patent: 4902614 (1990-02-01), Wakabayashi et al.
patent: 4987071 (1991-01-01), Cech et al.
patent: 4988496 (1991-01-01), Srinivasan et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5087571 (1992-02-01), Leder et al.
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5106951 (1992-04-01), Morgan, Jr. et al.
patent: 5110833 (1992-05-01), Mosbach
patent: 5162215 (1992-11-01), Bosselman et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5169784 (1992-12-01), Summers et al.
patent: 5175383 (1992-12-01), Leder et al.
patent: 5175384 (1992-12-01), Krimpenfort et al.
patent: 5204244 (1993-04-01), Fell et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5221778 (1993-06-01), Byrne et al.
patent: 5225539 (1993-07-01), Winter
patent: 5242687 (1993-09-01), Tykocinski et al.
patent: 5243041 (1993-09-01), Fernandez-Pol
patent: 5254678 (1993-10-01), Haseloff et al.
patent: 5266317 (1993-11-01), Tomalski et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5288641 (1994-02-01), Roizman
patent: 5328834 (1994-07-01), Ngo et al.
patent: 5347075 (1994-09-01), Sorge
patent: 5359051 (1994-10-01), Cook et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5395750 (1995-03-01), Dillon et al.
patent: 5463564 (1995-10-01), Agrafiotis et al.
patent: 5482856 (1996-01-01), Fell, Jr. et al.
patent: 5506337 (1996-04-01), Summerton et al.
patent: 5545808 (1996-08-01), Hew et al.
patent: 5567607 (1996-10-01), Zhao et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5591624 (1997-01-01), Barber et al.
patent: 5633076 (1997-05-01), DeBoer et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5698435 (1997-12-01), Robinson et al.
patent: 5707815 (1998-01-01), Charo et al.
patent: 5716613 (1998-02-01), Guber et al.
patent: 5716826 (1998-02-01), Gruber et al.
patent: 5716832 (1998-02-01), Barber et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5780009 (1998-07-01), Karatzas et al.
patent: 5780225 (1998-07-01), Karatzas et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5817491 (1998-10-01), Yee et al.
patent: 5840479 (1998-11-01), Little et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 5849288 (1998-12-01), Reisner
patent: 5851529 (1998-12-01), Guber et al.
patent: 5872005 (1999-02-01), Wang et al.
patent: 6271344 (2001-08-01), Turley
patent: 0415731 (1991-03-01), None
patent: 0440216 (1991-08-01), None
patent: 0612844 (1994-08-01), None
patent: 0 721 012 (1996-07-01), None
patent: 0721012 (1996-10-01), None
patent: 0360257 (1996-11-01), None
patent: WO 89/01973 (1989-03-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 90/07862 (1990-07-01), None
patent: WO 90/07936 (1990-07-01), None
patent: WO 91/00285 (1991-01-01), None
patent: WO 92/15677 (1992-09-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 93/10218 (1993-05-01), None
patent: WO 93/11230 (1993-06-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 93/20242 (1993-10-01), None
patent: WO 93/21312 (1993-10-01), None
patent: WO 93/25234 (1993-12-01), None
patent: WO 93/25698 (1993-12-01), None
patent: WO 94/03622 (1994-02-01), None
patent: WO 92/06693 (1994-04-01), None
patent: WO 95/02566 (1995-01-01), None
patent: WO 95/04277 (1995-02-01), None
patent: WO 95/10607 (1995-04-01), None
patent: WO 95/12387 (1995-05-01), None
patent: WO 95/16209 (1995-06-01), None
patent: WO 95/16712 (1995-06-01), None
patent: WO 95/16918 (1995-06-01), None
patent: WO 95/24186 (1995-09-01), None
patent: WO 95/24929 (1995-09-01), None
patent: WO 95/30642 (1995-11-01), None
patent: WO 96/00148 (1996-01-01), None
patent: WO 97/38098 (1997-10-01), None
patent: WO 9738098 (1997-10-01), None
patent: WO 99/01164 (1999-01-01), None
patent: 0 950 708 (1999-10-01), None
patent: WO 00/01841 (2000-01-01), None
patent: WO 00/29447 (2000-05-01), None
patent: WO 00/39166 (2000-07-01), None
patent: WO 01/80899 (2001-11-01), None
patent: WO 02/13848 (2002-02-01), None
patent: WO 02/28415 (2002-04-01), None
Chao, et al., “The characterization of a human RHAMM cDNA: conservation of they hyaluronan-binding domains”,Gene,vol. 174, No. 2, (1996), pp. 299-306.
Jean, et al., “Unmasking by a Hyaluronan-binding site of the BX7B type in the H3 heavy chain of the inter-alpha-inhibitor family”,European Journal of Biochemistry,vol. 268, No. 3, (Feb. 1, 2001), pp. 544-553.
Volker, et al., “The human hyaluron receptor RHAMM is expressed as an intracellular protein in breast cancer cells”,J. Cell Science,vol. 111, (1998), pp. 1685-1694.
International Search Report of Aug. 22, 2001 in PCT Application No. PCT/100/01534 (copending application).
Bauer, et al., “A genetic enrichment for mutations constructed by oligodeoxynucleotide-directed mutagenesis”,Gene,37:73-81, (1985).
Bird, et al., “Single-chain antigen-binding proteins”,Science,242:423-426, (1988).
Brinster, et al., “Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs”,Proc. Natl. Acad. Sci. U.S.A.,82:4438-4442, (1985).
Clothia, et al., “Domain association in immunoglobulin molecules”,J. Mol. Biol.,186:651, (1985).
Craik, et al., “Use of oligonucleotides for site-specific mutagenesis”,BioTechniques,pp. 12-19, (Jan. 1985).
Curiel, et al., “High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes”,Hum. Gene. Ther.,3:147-154, (1992).
Drinkwater, et al., “Chemically induced mutagenesis in a shuttle vector with a low-background mutant frequency”,PNAS,83:3402-3406, (1986).
Fisher-Hoch, et al., “Protection of rhesus monkeys fro
Cruz Tony
Pastrak Aleksandra
Turley Eva A.
Carlson Karen Cochrane
Liu Samuel Wei
Transition Therapeutics Inc.
LandOfFree
Compositions and methods for treating cellular response to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating cellular response to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating cellular response to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519455